Read Time: 1 minute
The supply of both generic and branded drugs may be interrupted by events in any of three key categories: market-wide supply constraints, product-specific issues, and reimbursement and market access limitations. A diverse set of root causes means that there is no single “silver bullet” solution to ending drug shortages. While each drug shortage is unique, we can build supply chain resiliency by understanding root causes and deploying targeted policy solutions to enhance the reimbursement and market access landscape, incentivize supply preservation programs, and improve supply chain visibility.
To learn more about McKesson’s actions, advocacy, and industry partnerships to address drug shortages, visit McKesson.com/DrugShortages, where you’ll also find our public policy team’s most recent white paper, Drug Shortages: Root Causes and Recommended Solutions (PDF, 217 KB).
Ready to learn how McKesson is working to help your health system achieve more? Contact our team now.
Share
Post
Post
Email